Substituted reverse pyrimidine Bmi-1 inhibitors
US10428050B2 · kind B2 · utility
1Cited by
16References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 2013 |
| Grant date | Oct 1, 2019 |
| Priority date | — |
| Expiry date | Nov 21, 2033 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.